FL-LUMOS-DIAGNOSTICS
5.2.2020 13:26:12 CET | Business Wire | Press release
Lumos Diagnostics announced the closing of U.S. $15 million in Series A funding from Planet Innovation , an Australia-based healthtech innovation and commercialization company. This funding will support the international commercial expansion of the FebriDx® rapid point-of-care (POC) test, the FebriDx U.S. FDA pivotal clinical trial, and additional development and manufacturing resources for the company’s expanding full-service POC business.
Lumos Diagnostics, a spinout from Planet Innovation, merged with RPS Diagnostics in May 2019, creating a diverse healthcare company that combines the FebriDx test and commercial experience with a novel and proprietary digital reader platform. Sam Lanyon, chairman of the board for Lumos Diagnostics and co-chief executive officer for Planet Innovation states, “Planet Innovation is focused on breakthrough technology and making investments that will have a global impact on healthcare. It is obvious that Lumos Diagnostics is poised for rapid growth and Planet Innovation is keen to support and accelerate the process.”
FebriDx is a rapid POC test that provides clinicians with an in-office assessment of the body’s immune response to acute respiratory infection (ARI). More than 50% of all unnecessary antibiotic prescriptions are for outpatient ARIs which may be associated with nonspecific flu-like symptoms, including fever, sore throat, cough, nasal congestion and fatigue. Only bacterial infections benefit from antibiotic treatment. The single-use FebriDx test identifies patients of all ages within 10 minutes who have a clinically significant underlying infection and aids in the differentiation of viral and bacterial ARIs through the simultaneous detection of both Myxovirus resistance protein A (MxA) and C-reactive protein (CRP) directly from a fingerstick blood sample.
MxA is highly specific and elevates in the presence of acute viral infection while CRP is a nonspecific inflammatory protein that elevates in the presence of clinically significant infection. The simultaneous, combined interpretation of both MxA and CRP leads to sensitive and specific test results. With a 97-99% negative predictive value for ruling out bacterial infections, the FebriDx test may help to limit the amount of unnecessary antibiotic prescriptions that can lead to avoidable adverse reactions and antibiotic resistance, resulting in lower costs.
Robert Sambursky, MD, president and chief executive officer of Lumos Diagnostics states, “FebriDx helps advise antibiotic decisions for outpatient ARI while saving clinician time, improving workflow and reducing overall costs. The novel digital reader technology that Lumos offers as part of our complete POC service solution will be used in the next generation digital FebriDx test, providing faster time to results, identification of the rare co-infection and enhanced objectivity of test result interpretations.”
Lumos Diagnostics
Lumos Diagnostics provides rapid, cost-effective and complete point-of-care (POC) diagnostic test solutions that utilize proprietary digital reader platforms to help healthcare professionals more accurately diagnose and manage diseases and medical conditions. Lumos provides assay development and manufacturing services for customized POC tests as well as directly develops, manufactures and will commercialize a suite of proprietary Lumos-branded POC tests that focus on the systemic host immune response. Lumos’s tests target infectious and inflammatory diseases with unmet diagnostic needs. Actionable results lead to less unnecessary treatments with associated adverse events, reduced spread of disease and more effective clinical management and therapeutic decisions.
The FebriDx test has received HealthCanada approval, Saudi Arabia FDA clearance, Singapore HSA registration, Pakistan DRAP registration and is CE marked for sale in Europe. At this time, FebriDx has not received U.S. Food and Drug Administration (FDA) clearance and is not commercially available in the United States. For more information on Lumos Diagnostics, visit www.lumosdiagnostics.com , and for more information on FebriDx, visit www.febridx.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200205005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International and Bank Partners Achieve Real-Time Cross-Bank Liquidity Management through Tokenised Deposits via CeBM under HKMA’s EnsembleTX3.11.2026 05:10:00 CET | Press release
Transfers were among the first batch of live transactions completed under EnsembleTX, unlocking 24/7 liquidity access and near-instant settlement Following the Hong Kong Monetary Authority’s (HKMA) announcement on interbank settlement of tokenised deposit transactions under EnsembleTX, Ant International announced that it has achieved real-time cross-bank liquidity management with its key banking partners as part of its active participation in EnsembleTX. In close collaboration with Bank of China (Hong Kong) (“BOCHK”, SEHK: 2388), China Construction Bank (Asia) (“CCB (Asia)”) and HSBC (SEHK: 5), Ant International successfully completed a series of live HKD interbank transactions between September and October 2026: BOCHK interbank transactions with CCB (Asia) CCB (Asia) interbank transactions HSBC interbank transactions Executed using tokenised deposit settled through the HKMA’s Central Bank Money (CeBM), the transfers were initiated via Ant International’s proprietary blockchain-based w
SuperElastic* Material Unveiled by Angelalign2.11.2026 18:46:00 CET | Press release
New, Improved Clear Aligner Material Gives Orthodontists More Control Angelalign Technology Inc. (6699.HK) (“Angel”)http://www.angelaligner.com, a global clear aligner leader, today unveiled SuperElastic (MC-SE*), a new propietary aligner material that is a significant breakthrough in performance over its current material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102654659/en/ Specialists in orthodontics have long asked for new aligner materials that enable better treatment for complex cases: biologically safe force levels, a large elastic working range, and strength and toughness. MC-SE* provides all of them. “Angel is commited to innovation and never settling for 'good enough'. MC-SE* is the result of seven years of materials research, testing and manufacturing optimization. The new material aims to create a new generation of aligner material that allows orthodonists to differentiate their treatment from other tre
Galderma Announces Proposed Board Appointments and Chief Financial Officer Transition2.11.2026 18:00:00 CET | Press release
The Company will hold an Extraordinary General Meeting on December 3, 2026 to further reinforce its Board of DirectorsAd hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced proposed changes to its Board of Directors, aimed at further strengthening its governance and supporting its long-term growth. The company also announced that Luigi La Corte, Chief Financial Officer (CFO), has decided to leave Galderma to pursue a significant new opportunity. Luigi La Corte will continue to fulfil his responsibilities as CFO during the transition period, supporting business continuity and a smooth handover. The company will communicate further details regarding succession arrangements and the transition timeline in due course. The Board of Directors is proposing the election of Rosalind Brewer and Petra Rumpf as new Board members. Both candidates bring extensive leadership and governance experience, alongside expertise span
Donaldson Introduces Alpha-Pore™ Technology Platform for Extended Sterile Filtration Performance2.11.2026 15:35:00 CET | Press release
Donaldson Company, Inc. (NYSE: DCI), a leading worldwide manufacturer of innovative filtration products and solutions, today announced Alpha‑Pore™ technology, a next generation sterile filtration platform engineered to extend filter service life while maintaining critical process performance. Built for critical applications, Alpha‑Pore technology enables longer filter run time compared with competitive single- and dual-layer polyethersulfone (PES) membrane filters, while maintaining flow characteristics, sterility assurance, and process integrity.* The platform is designed to help manufacturers improve operational efficiency through fewer changeouts and more consistent performance over time. Engineered for Extended Performance Sterile filtration processes often require balancing run time with key performance parameters such as flow, differential pressure, and contaminant retention. Alpha‑Pore technology is designed to achieve all three. By optimizing pore structure and filter architect
SBC Medical Forms Capital and Business Alliance with AtomicSoftware, Provider of the medicalforce Clinic Management Platform Used by 800+ Clinics in Japan2.11.2026 15:00:00 CET | Press release
Companies to co-develop AI features, starting with physician documentation support, to enhance medicalforce and SBC Medical’s in-house systems and drive per-clinic productivity and profitability SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that it entered into a capital and business alliance agreement on October 26, 2026, with AtomicSoftware Inc. (“AtomicSoftware”), the Tokyo-based provider of medicalforce, an all-in-one software-as-a-service (SaaS) platform for clinics. In connection with the alliance, SBC Medical has invested ¥600 million (approximately US$3.8 million) in AtomicSoftware’s Series C funding round. The two companies will co-develop AI features, beginning with a feature that supports physicians in preparing medical records. Key HighlightsProven platform: medicalforce is used by more than 800 clinics*1 in J
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom